Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival.
Bone metastasis
Non-small-cell lung carcinoma
Orthotopic mouse model
Osimertinib
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
01
05
2020
accepted:
15
05
2020
pubmed:
14
7
2020
medline:
14
7
2020
entrez:
14
7
2020
Statut:
ppublish
Résumé
Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell line H1975, expressing red fluorescent protein (H1975-RFP), was orthotopically injected to the tibia of nude mice. The established mouse models were randomized into four treatment groups of nine mice: Control; BV alone; osimertinib alone; osimertinib and BV combination. The tumors were observed by non-invasive fluorescence imaging. Osimertinib, with or without BV, caused tumor regression, increased mouse survival, and bone remodeling in the bone metastasis models. These results suggest that osimertinib is a promising clinical option for NSCLS patients with bone metastasis.
Identifiants
pubmed: 32659740
pii: S1936-5233(20)30318-1
doi: 10.1016/j.tranon.2020.100826
pmc: PMC7356269
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100826Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TH, NS, JHP, TH, YS, GZ, KI and RMH are or were unsalaried associates of AntiCancer Inc. AntiCancer Inc. uses PDOX models for contract research. The Authors declare that there are no potential conflicts of interest.
Références
Clin Lung Cancer. 2019 Jul;20(4):e492-e494
pubmed: 31085043
Ther Adv Med Oncol. 2014 May;6(3):101-14
pubmed: 24790650
Clin Lung Cancer. 2019 May;20(3):e402-e406
pubmed: 30905617
BMC Cancer. 2019 Apr 3;19(1):303
pubmed: 30943924
JAMA Oncol. 2019 Aug 8;:
pubmed: 31393548
Lancet Oncol. 2019 May;20(5):625-635
pubmed: 30975627
Sci Rep. 2015 Dec 22;5:18670
pubmed: 26690845
Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305
pubmed: 25344762
Transl Oncol. 2019 Apr;12(4):640-645
pubmed: 30807997
Cancer Chemother Pharmacol. 2019 May;83(5):809-815
pubmed: 30758647
Clin Cancer Res. 2009 May 15;15(10):3484-94
pubmed: 19447865
J Thorac Dis. 2019 Sep;11(Suppl 15):S1831-S1834
pubmed: 31632761
Pathol Oncol Res. 2014 Jan;20(1):107-12
pubmed: 23852459
Biochem Biophys Res Commun. 2019 May 28;513(2):326-331
pubmed: 30955860
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Mol Clin Oncol. 2017 Nov;7(5):897-902
pubmed: 29181185
Cancer Res. 1998 Oct 1;58(19):4217-21
pubmed: 9766640
Ann Oncol. 2012 Sep;23(9):2215-2222
pubmed: 22357445
Int J Oncol. 2015 Sep;47(3):849-56
pubmed: 26179332